Compare ADMA Biologics Inc (ADMA) vs Weibo Corp (WB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Weibo Corp — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Weibo Corp trades at $7.66 (market cap $1.85B). The key difference: ADMA Biologics Inc is the larger of the two by market cap, and Weibo Corp pays a 8.16% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | WB | |
|---|---|---|
Market Cap | $2.13B | $1.85B |
Sector | Health | Media |
52-Week High | $20.38 | $12.83 |
52-Week Low | $7.60 | $7.20 |
Enterprise Value | $2.20B | $1.12B |
Dividend Yield | — | 8.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Weibo (WB) trades at $7.47, up 1.49% today, with a bullish technical signal and strong fundamentals including a 25.55% net margin and 10.33% ROE. Recent quarterly earnings missed expectations, but the company maintains robust cash flow and a high dividend yield. Valuation metrics appear attractive with a P/E of 5.29 and P/B of 0.48, while analyst sentiment is mixed with 45% buy ratings.
The outlook balances deep value against competitive pressures. The stock offers significant upside if monetization improves, but faces risks from user engagement declines and rivalry with Douyin. Near-term catalysts include Q2 2026 earnings and dividend payments, though consistent EPS misses warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
